|
|
 Previous Article | Table of Contents | Next Article 
Blood, 1 April 2002, Vol. 99, No. 7, pp. 2626-2627
CORRESPONDENCE
To the editor:
Treatment and outcome of infants with acute myeloid leukemia
We read with interest the article reporting the results of the
Japan Infant Leukemia Study Group treatment of infants with acute
myeloid leukemia (AML) on the ANLL91 protocol. The event-free survival
reported for their patients treated with intensive chemotherapy is
quite impressive.1 The authors were very thorough in
comparing their results with those of other cooperative
groups. Unfortunately, they did not use the most recently
published data from the US Children's Cancer Group (CCG) in their
Table 3.1 The updated results of CCG-2891,2
published in January 2001, report the responses of 116 infants
treated with allogeneic bone marrow transplant, autologous bone marrow
transplant, or chemotherapy alone. Those infants achieved an 8-year
actuarial survival of 71% (allogeneic transplant), 40%
(autologous transplant), and 61% (intensive
chemotherapy).2 These numbers are significantly different
from the results published in 1996, and compare quite favorably with
those reported by Kawasaki et al (72%-74% 3-year survival for a
total of 35 patients). While the use of the more recently published CCG
results does not change substantively the results or conclusions
reached by Kawasaki et al, comparison with the more recent results
provides a more appropriate context for evaluating the significance of
their findings. These studies complement each other, providing evidence
that an age of younger than 1 year is probably not an independent
adverse prognostic factor for children with AML, supporting the use of intensive chemotherapy when there is no allogeneic bone marrow donor available.
David M. Loeb and Robert J. Arceci
Correspondence: Robert J. Arceci, Division of Pediatric
Oncology, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
University, Baltimore, MD 21231
References
1.
Kawasaki H, Isoyama K, Eguchi M, et al.
Superior outcome of infant acute myeloid leukemia with intensive chemotherapy: results of the Japan Infant Leukemia Study Group.
Blood.
2001;98:3589-3594[Abstract/Free Full Text].
2.
Woods WG, Neudorf S, Gold S, et al.
A comparison of allogeneic bone marrow transplantation, autologous bone marrow transplantation, and aggressive chemotherapy in children with acute myeloid leukemia in remission: a report from the Children's Cancer Group.
Blood.
2001;97:56-62[Abstract/Free Full Text].
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
Related Article in Blood Online:
-
Superior outcome of infant acute myeloid leukemia with intensive chemotherapy: results of the Japan Infant Leukemia Study Group
- Hajime Kawasaki, Keiichi Isoyama, Mariko Eguchi, Shigeyoshi Hibi, Naoko Kinukawa, Yoshiyuki Kosaka, Takanori Oda, Megumi Oda, Shin-ichiro Nishimura, Masue Imaizumi, Takayuki Okamura, Teruaki Hongo, Hiroji Okawa, Shuki Mizutani, Yasuhide Hayashi, Ichiro Tsukimoto, Nanao Kamada, and Eiichi Ishii
Blood 2001 98: 3589-3594.
[Abstract]
[Full Text]
[PDF]
|
|
